MBX Biosciences registers Phase 3 trial of canvuparatide for hypoparathyroidism
The trial is recruiting adults with hypoparathyroidism to test once-weekly canvuparatide against placebo across 12 US sites.
MBX Biosciences has one Phase 3 study active in its trial record this week.
- Canvuparatide (MBX 2109), a once-weekly subcutaneous drug-device combination, is being studied in a Phase 3, randomized, placebo-controlled trial for adult patients with hypoparathyroidism, registered as NCT07699471. The study is recruiting, with an estimated enrollment of 160 participants1 and an actual start date of 2026-08-261. The primary outcome assesses the effect of pooled weekly doses of canvuparatide on responder rates among patients, measured over a 26 week period1, with primary completion estimated for 2028-011.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.